Literature DB >> 16460776

Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.

Ranajit Pal1, V S Kalyanaraman, B C Nair, Stephen Whitney, Timothy Keen, Lindsey Hocker, Lauren Hudacik, Nicolas Rose, Innocent Mboudjeka, Siyuan Shen, Te-Hui Wu-Chou, David Montefiori, John Mascola, Philip Markham, Shan Lu.   

Abstract

The immunogenicity of a poylvalent HIV-1 vaccine comprised of Env antigens from primary R5 isolates was evaluated in rhesus macaques. DNA vaccines encoding four Env antigens from multiple HIV-1 subtypes and HIV-1 Gag antigen from a single subtype elicited a persistent level of binding antibodies to gp120 from multiple HIV-1 isolates that were markedly enhanced following boosting with homologous gp120 proteins in QS-21 adjuvant irrespective of the route of DNA immunization. These sera neutralized homologous and, to a lesser degree, heterologous HIV-1 isolates. Four of the six immunized animals were completely protected following rectal challenge with a SHIV encoding Env from HIV-1(Ba-L), whereas the virus load was reduced in the remaining animals compared to naïve controls. Hence priming with DNA encoding Env antigens from multiple HIV-1 clades followed by boosting with homologous Env proteins elicits anti-HIV-1 immune responses capable of protecting macaques against mucosal transmission of R5 tropic SHIV isolate.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16460776     DOI: 10.1016/j.virol.2005.12.029

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  53 in total

1.  Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.

Authors:  Jeffrey D Lifson; Nancy L Haigwood
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

Review 2.  Combination DNA plus protein HIV vaccines.

Authors:  Shan Lu
Journal:  Springer Semin Immunopathol       Date:  2006-09-21

3.  A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague.

Authors:  Hitoki Yamanaka; Teri Hoyt; Xinghong Yang; Sarah Golden; Catharine M Bosio; Kathryn Crist; Todd Becker; Massimo Maddaloni; David W Pascual
Journal:  Infect Immun       Date:  2008-08-11       Impact factor: 3.441

4.  Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1).

Authors:  Aaron Wallace; Kim West; Alan L Rothman; Francis A Ennis; Shan Lu; Shixia Wang
Journal:  Hum Vaccin Immunother       Date:  2013-08-13       Impact factor: 3.452

Review 5.  New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.

Authors:  Thomas Musich; Marjorie Robert-Guroff
Journal:  Expert Rev Vaccines       Date:  2016-03-16       Impact factor: 5.217

6.  The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers.

Authors:  Jeffrey S Kennedy; Mary Co; Sharone Green; Karen Longtine; Jaclyn Longtine; Melissa A O'Neill; Janice P Adams; Alan L Rothman; Qiao Yu; Renita Johnson-Leva; Ranajit Pal; Shixia Wang; Shan Lu; Phillip Markham
Journal:  Vaccine       Date:  2008-06-25       Impact factor: 3.641

Review 7.  Synthetic DNA vaccine strategies against persistent viral infections.

Authors:  Daniel O Villarreal; Kendra T Talbott; Daniel K Choo; Devon J Shedlock; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2013-05       Impact factor: 5.217

Review 8.  Rational antibody-based HIV-1 vaccine design: current approaches and future directions.

Authors:  Laura M Walker; Dennis R Burton
Journal:  Curr Opin Immunol       Date:  2010-03-17       Impact factor: 7.486

9.  An IL-12 DNA vaccine co-expressing Yersinia pestis antigens protects against pneumonic plague.

Authors:  Hitoki Yamanaka; Teri Hoyt; Richard Bowen; Xinghong Yang; Kathryn Crist; Sarah Golden; Massimo Maddaloni; David W Pascual
Journal:  Vaccine       Date:  2008-10-26       Impact factor: 3.641

Review 10.  Viral sequence diversity: challenges for AIDS vaccine designs.

Authors:  Sean P McBurney; Ted M Ross
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.